Genitourinary Cancers | Specialty

The genitourinary cancers condition center is a comprehensive resource for clinical news and expert insights on genitourinary cancers. Read more at OncLive.

Long-Term Data Demonstrate Sustained DFS Benefit With Adjuvant Pembrolizumab in ccRCC

June 1st 2025

Adjuvant pembrolizumab showed maintained OS and DFS vs placebo in patients with ccRCC at the 5-year analysis.

Nivolumab/Ipilimumab Maintains Prolonged Survival and Generates Durable Responses in Advanced RCC

June 1st 2025

First-line nivolumab/ipilimumab demonstrated sustained survival signals and responses vs sunitinib in previously untreated advanced RCC.

Dr Matrana on the Persisting Need For Validated Biomarkers to Guide Treatment Selection in RCC

May 31st 2025

Marc R. Matrana, MD, discusses the ongoing need for validated biomarkers to guide treatment selection in renal cell carcinoma.

Dr Matrana on Advantages and Challenges of the Expanding First-Line RCC Treatment Paradigm

May 30th 2025

Marc Matrana, MD, discusses how the expansion of the frontline RCC treatment paradigm opens the door to further questions regarding personalized treatment.

Dr Vento on the Role of IO/TKI Combos in Non–Clear Cell RCC

May 29th 2025

Joseph Vento, MD, highlights the role of IO/TKI combinations for the treatment of patients with non–clear cell renal cell carcinoma.

Health Canada, European Commission Approve Subcutaneous Nivolumab in the Same Solid Tumor Indications as IV Formulation

May 28th 2025

Nivolumab has been approved for subcutaneous use across several adult solid tumor indications that have an existing indication for intravenous use.

Dr Bowman on Distinctions Between Disease Characteristics and Treatment Response in ccRCC vs Non-ccRCC

May 27th 2025

I. Alex Bowman, MD, discusses the differences in disease presentation between ccRCC and non-ccRCC, as well as standard treatments for these subtypes.

Dr Nguyen on the Evolving Landscape of Adjuvant Therapy in Localized ccRCC

May 27th 2025

Charles B. Nguyen, MD, discusses the evolving landscape of adjuvant therapy in localized clear cell renal cell carcinoma.

Dr Tang on the Implementation of Metastasis-Directed Radiotherapy in Oligometastatic ccRCC

May 23rd 2025

Chad Tang, MD, discusses potential roadblocks for the clinical use of metastasis-directed radiotherapy for patients with oligometastatic ccRCC.

Dr Wang on Key Findings From a Study of the Tumor Microenvironment in ccRCC

May 23rd 2025

Yufei Wang, PhD, discusses how the metastasis of ccRCC could rewire the tumor microenvironment and lead to increased immunosuppression and fibrosis.

Dr Matrana on the Importance of Combination Therapies in Metastatic RCC

May 23rd 2025

Marc R. Matrana, MD, emphasizes the need for combination therapies for the treatment of patients with advanced or metastatic renal cell carcinoma.

Experts Spotlight Noteworthy GU Cancer Abstracts Ahead of the 2025 ASCO Annual Meeting

May 22nd 2025

Ahead of the 2025 ASCO Annual Meeting, experts in genitourinary cancers share the most anticipated research being presented during the meeting.

Dr Tykodi on the Current Limitations of Cabozantinib-Based Triplets in Advanced RCC

May 20th 2025

Scott Tykodi, MD, PhD, discusses the challenges with developing effective, less toxic triplet regimens for patients with advanced RCC.

Combination Regimens Offer Options in Frontline RCC as Novel Agents Advance Through Pipeline

May 19th 2025

During an OncLive Peer Exchange filmed during ASCO GU, expert investigators discussed significant updates in the RCC space.

Dr Hall on Unmet Needs in Later-Line RCC

May 15th 2025

Evan T. Hall, MD, Mphil, discusses several avenues for future research in later-line renal cell carcinoma.

Dr Beckermann on the Rationale for Evaluating Tivozanib/Nivolumab After IO-Based Therapy in RCC

May 14th 2025

Kathryn E. Beckerman, MD, PhD, details the rationale for evaluating tivozanib/nivolumab following immune checkpoint inhibitors in renal cell carcinoma.

Sitravatinib/Nivolumab Shows Modest Activity in Progressive Metastatic Clear Cell RCC Before Trial Termination

May 14th 2025

Sitravatinib plus nivolumab did not produce significant antitumor activity or survival outcomes in patients with progressive metastatic clear cell RCC.

Belzutifan Displays Robust Activity in VHL-Associated RCC

May 12th 2025

Belzutifan was safe and effective in patients with von Hippel-Lindau–associated RCC and other neoplasms.

Limited Role for ICI Rechallenge in RCC Spurs Interest in More Tailored Later-Line Strategies

May 8th 2025

Evan T. Hall, MD, MPhil, discusses the limited potential for immunotherapy rechallenge in patients with RCC and challenges with later-line RCC management.

Giants of Cancer Care® Announces the 13th Annual Class of Inductees

May 7th 2025

OncLive announces the inductees of the 13th annual Giants of Cancer Care recognition program.